DPI Achieves Prestigious ISO 27001 Certification for Information Security Management
7.4.2025 09:35:00 CEST | Business Wire | Press Release
Datalec Precision Installations (DPI), a leading provider of world-class data centre solutions specialising in M&E and Connectivity design, bespoke manufacturing, construction, and installation services, proudly announces its achievement of the ISO/IEC 27001:2022 certification for Information Security Management. This globally recognised standard underscores DPI’s commitment to safeguarding sensitive data and maintaining the highest levels of operational security.
This milestone comes at a pivotal time as the industry transitions to the updated ISO/IEC 27001:2022 framework ahead of the October 2025 compliance deadline. DPI’s certification reflects its proactive approach to adopting modernised controls and addressing today’s cyber and information security challenges, ensuring that clients benefit from robust protection in an increasingly digital landscape.
"A Commitment to Excellence in Security"
“At DPI, protecting our clients’ and employees’ sensitive information is at the core of our operations,” said Glenn Stephenson, Operations Director Electronic Security and Information Security Officer at DPI. “Achieving ISO 27001:2022 certification demonstrates our unwavering dedication to meeting the highest global standards for information security. This accomplishment not only strengthens our clients’ trust but also positions us as a leader in secure data centre solutions.”
Key Benefits for DPI Clients
DPI’s ISO 27001 certification delivers tangible advantages for its global clientele:
- Enhanced Data Protection: Implementation of advanced security controls ensures confidentiality, integrity, and availability of data.
- Regulatory Compliance: Alignment with international regulations such as GDPR, HIPAA, and PCI DSS builds trust and simplifies compliance requirements.
- Proactive Risk Management: A structured approach to identifying and mitigating risks minimizes potential disruptions.
- Operational Efficiency: Streamlined processes lead to improved productivity and cost savings.
This achievement further integrates with DPI’s robust suite of certifications - ISO 9001 (Quality Management), ISO 14001 (Environmental Management), and ISO 45001 (Occupational Health & Safety) - creating a comprehensive Integrated Management System that drives excellence across all facets of its operations.
DPI holds ISO 27001 as a benchmark for trustworthiness and operational excellence. As cybersecurity threats evolve, this certification positions DPI as a preferred partner for clients seeking secure, scalable solutions tailored to meet the demands of modern digital infrastructure.
For more information about Datalec Precision Installations (DPI) and its comprehensive suite of data centre solutions, visit https://datalecltd.com
About Datalec
Datalec Precision Installations provides world-class, global data centre solutions, specialising in M&E and connectivity design, bespoke manufacturing, construction, and installation services. Supported by unmatched technical expertise we offer consultancy, technical and critical cleaning, electronic security, and managed services to address every data centre need.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250407751671/en/
Contacts
Media Contact
Ilissa Miller
iMiller Public Relations
Email: datalec@imillerpr.com
Tel: 1.914.315.6424
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom